5 common mistakes companies face when navigating French Early Access Programs

White papers - 26 April 2023

Pharmablue / White papers / 5 common mistakes companies face when navigating French Early Access Programs

5 common mistakes companies face when navigating French Early Access Programs

 

Download the 5 common mistakes companies face when navigating French Early Access Programs:

 

  • Planning from the early stage
  • Not enough European/French resources available
  • Partner with a “low-cost” Exploitant
  • Early Access Programs – Differences in Regulation and Implementation
  • Changing regulations that need to be monitored

 

Download the
Case Study


    PharmaBlue undertakes to comply with the regulations in force applicable to the processing of personal data and, in particular, Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 applicable as from 25 May 2018 (hereinafter, "the General Data Protection Regulations" or GPDR) and the national laws resulting therefrom.
    Any inquiries, correction or declaration of event related to personal data processed should be sent to: our contact page
    Learn more

     

     

    Thank you for your interest in PharmaBlue.

    You can download the file by clicking on “Download”.

    Download